Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Nguyen, HG; Tilki, D; Dall'Era, MA; Durbin-Johnson, B; Carballido, JA; Chandrasekar, T; Chromecki, T; Ciancio, G; Daneshmand, S; Gontero, P; Gonzalez, J; Haferkamp, A; Hohenfellner, M; Huang, WC; Espinós, EL; Mandel, P; Martinez-Salamanca, JI; Master, VA; McKiernan, JM; Montorsi, F; Novara, G; Pahernik, S; Palou, J; Pruthi, RS; Rodriguez-Faba, O; Russo, P; Scherr, DS; Shariat, SF; Spahn, M; Terrone, C; Vergho, D; Wallen, EM; Xylinas, E; Zigeuner, R; Libertino, JA; Evans, CP.
Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis.
J Urol. 2015; 194(2):304-308 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Chromecki Thomas
Zigeuner Richard
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 2
| |
Abstract:
The impact of cardiopulmonary bypass in level III-IV tumor thrombectomy on surgical and oncologic outcomes is unknown. We determine the impact of cardiopulmonary bypass on overall and cancer specific survival, as well as surgical complication rates and immediate outcomes in patients undergoing nephrectomy and level III-IV tumor thrombectomy with or without cardiopulmonary bypass. We retrospectively analyzed 362 patients with renal cell cancer and with level III or IV tumor thrombus from 1992 to 2012 at 22 U.S. and European centers. Cox proportional hazards models were used to compare overall and cancer specific survival between patients with and without cardiopulmonary bypass. Perioperative mortality and complication rates were assessed using logistic regression analyses. Median overall survival was 24.6 months in noncardiopulmonary bypass cases and 26.6 months in cardiopulmonary bypass cases. Overall survival and cancer specific survival did not differ significantly in both groups on univariate analysis or when adjusting for known risk factors. On multivariate analysis no significant differences were seen in hospital length of stay, Clavien 1-4 complication rate, intraoperative or 30-day mortality and cancer specific survival. Limitations include the retrospective nature of the study. In our multi-institutional analysis the use of cardiopulmonary bypass did not significantly impact cancer specific survival or overall survival in patients undergoing nephrectomy and level III or IV tumor thrombectomy. Neither approach was independently associated with increased mortality on multivariate analysis. Greater surgical complications were not independently associated with the use of cardiopulmonary bypass. Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Carcinoma, Renal Cell - surgery
Cardiopulmonary Bypass -
Female -
Humans -
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Kidney Neoplasms - surgery
Male -
Middle Aged -
Neoplastic Cells, Circulating -
Nephrectomy - methods
Retrospective Studies -
Survival Rate - trends
Thrombectomy - methods
Thrombectomy - epidemiology
Vena Cava, Inferior -
Venous Thrombosis - etiology
Venous Thrombosis - mortality
Venous Thrombosis - surgery

Find related publications in this database (Keywords)
carcinoma, renal cell
cardiopulmonary bypass
vena cava, inferior
survival
intraoperative complications
© Med Uni Graz Impressum